Mavenclad Alternatives Compared
Mavenclad | Betaseron | Kesimpta |
|
---|
Mavenclad (cladribine) | Betaseron (interferon beta-1b) | Kesimpta (ofatumumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Mavenclad may be given to people with relapsing forms of MS who have had an inadequate response to, or who are unable to tolerate other medications for MS that have a more favorable safety profile... View more |
Prescription only
Prescribed for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Colorectal Cancer, Multiple Sclerosis. Betaseron may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
More about Mavenclad (cladribine) | More about Betaseron (interferon beta-1b) | More about Kesimpta (ofatumumab) | ||||||||||||||||||||||||
Generic Status | ||||||||||||||||||||||||||
No lower-cost generic available |
No lower-cost generic available |
|||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Mavenclad has an average rating of 9.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Betaseron has an average rating of 7.0 out of 10 from a total of 7 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 14% reported a negative effect. |
Kesimpta has an average rating of 6.5 out of 10 from a total of 53 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 25% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: Mavenclad side effects in more detail. |
Common side effects include:
See also: Betaseron side effects in more detail. |
See also: Kesimpta side effects in more detail. |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Mavenclad prices and generic prices |
View all Betaseron prices |
View all Kesimpta prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other cladribine brands include: Cladribine Novaplus | Other interferon beta-1b brands include: Extavia | Other ofatumumab brands include: Arzerra | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
6.7 hours |
4.3 hours |
1476 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 463 drugs are known to interact with Mavenclad:
|
A total of 314 drugs are known to interact with Betaseron:
|
A total of 155 drugs are known to interact with Kesimpta:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
March 29, 2019 |
July 23, 1993 |
N/A |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.